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Melioidosis is an infectious disease of humans and
animals caused by Burkholderia pseudomallei (1). This
organism is widely distributed in rice field soil and in
stagnant water throughout the tropics (1-8). Although a major
disease in Southeast Asia and northern Australia,
melioidosis occurs sporadically throughout the world (often in
patients with a history of residence in these disease-endemic
areas) (1). Humans are usually infected by traumatic
inoculation of the organism from the soil or, rarely, by
inhalation or ingestion (1,7). Clinical manifestations are
protean, ranging from benign and localized abscess, to severe,
community-acquired pneumonia to fatal septicemia (1,3,4,7).
The two biotypes of B. pseudomallei are categorized by their
ability to assimilate L-arabinose (9). The arabinose non-
assimilators (Ara-) are virulent and can be isolated from both
clinical specimens and the environment, whereas the
arabinose assimilators (Ara+) are usually avirulent and
mainly found in the environment (9,10). Relapse, recrudes-
cence, or reinfection may occur in immunocompromised
patients under inappropriate antimicrobial treatment or
after resolution of primary infection (1,7,11,12).
In Taiwan in 1985, melioidosis was first reported in a
previously healthy patient with multilobar pneumonia, which
developed secondary to his near drowning in the Philippines
(13).  Since then, only six other cases have been reported
(14-18). In our study, an additional eight patients with
melioidosis found from 1996 to 2000 by National Taiwan
University Hospital (NTUH) were reported and microbio-
logic characteristics (including biotyping, cellular fatty
acid chromatograms, antimicrobial susceptibilities, and
genotyping) of the strains isolated from these patients were
evaluated.
Materials and Methods
Patients and Bacterial Isolates
From January 1980 to May 2000, eight patients with
melioidosis were treated at NTUH, a tertiary-care referral
center with 2,000 beds in northern Taiwan, and seven
patients reported to have melioidosis were treated at other
hospitals in Taiwan. Data on demographics, underlying
diseases, travel history, type of infection, antimicrobial
treatment, and outcome of these patients were analyzed.
Infections were considered indigenous if patients had no
history of residence or travel to China, Australia, or Southeast
Asia. A total of 17 isolates of B. pseudomallei from various
clinical specimens of the eight patients treated at NTUH were
studied. These isolates were identified by conventional
biochemical methods and confirmed by the API 20NE
identification system (Biomerieux, Basingstoke, UK) (19,20).
Susceptibility and Antibiotypes
The following antimicrobial agents were provided by
their manufacturers for use in this study: amoxicillin-
clavulanate (SmithKline Beecham, Welwyn Garden City,
UK); cefotaxime (Marion Merrell Dow, Cincinnati, OH);
ceftazidime (Glaxo, Greenford, UK); amoxicillin, cefepime,
aztreonam, and amikacin (Bristol-Meyer Squibb, Princeton,
NJ); imipenem (Merck Sharp & Dohme, Rahway, NJ);
meropenem (Sumitomo Pharmaceuticals, Osaka, Japan);
piperacillin-tazobactam (Wyeth-Ayerst Laboratories, Pearl
River, NY); flomoxef (Shionogi, Osaka, Japan); trovafloxacin
(Pfizer Inc., New York, NY); and ciprofloxacin and
moxifloxacin (Farbenfabriken Bayer GmbH, Leverkrusen,
Germany).  MICs of these antimicrobial agents were
determined by the agar dilution method according to
guidelines established by the National Committee for Clinical
Laboratory Standards (21). Isolates were grown overnight on
trypticase soy agar plates supplemented with 5% sheep blood
(BBL Microbiology Systems, Cockeysville, MD) at 37°C.
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Bacterial inocula were prepared by suspending the freshly
grown bacteria in sterile normal saline and adjusted to a 0.5
McFarland standard. Mueller-Hinton agar (BBL Microbiolo-
gy Systems) was used for susceptibility testing. With a Steers
replicator, an organism density of 104 CFU/spot was
inoculated onto the appropriate plate with various
concentrations of antimicrobial agents. Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were
included as control strains. Antibiotypes were considered
identical if all MICs tested were identical or within a twofold
dilution discrepancy (22).
Cellular Fatty Acid Chromatogram and Biotypes
Biotypes of these isolates were identified according to the
reaction profiles obtained by API 20NE. Arabinose utilization
was determined by growth on minimal salt agar containing
L-arabinose (0.2%) (9). Fatty acid methyl esters (FAMEs) of
these isolates were analyzed by gas-liquid chromatography
using a Hewlett-Packard 5890A (Hewlett-Packard; Avondale,
PA) as described previously (22). The software library used to
identify the B. pseudomallei was TSA, version 3.9 (Microbial
ID Inc., Newark, DE).
Strain Typing
Extraction of genomic DNA and polymerase chain
reaction (PCR) for determining random amplified polymor-
phic DNA (RAPD) patterns generated by arbitrarily primed
PCR of the 17 isolates of B. pseudomallei were performed as
previously described (22). Three oligonucleotide primers used
were: M13 (5'-TTATGTAAAACGACGGCCAG-3' (Gibco BRL
products, Gaithersburg, MD), ERIC1 (5'-GTGAATCCCCAG-
GAGCTTACAT-3' (Gibco Bethesda Research Laboratories
Products), and OPH-03 (5'-AGACGTCCAC-3') (Operon
Technologies, Inc., Alameda, CA). To interpret RAPD
patterns, both faint and intense bands were included (22).
The entire procedure, from bacterial growth to interpretation
of RAPD pattern, was repeated three times for each isolate to
confirm results. Patterns were considered identical only if
they differed by no more than one band. Isolates were defined
as being of the same strain (highly related isolates) if they had
identical antibiotypes, biotypes, and RAPD patterns.
Results
Clinical Characteristics of Patients
From January 1982 to May 2000, 17 episodes of infection
caused by B. pseudomallei were diagnosed in 15 patients in
Taiwan. All but one episode occurred between 1994 and 2000
(Figure 1; Table 1), indicating that cases have increased
substantially in recent years. In these 15 patients, 13 were
male; mean age was 64 years (range, 40 to 76 years). Patient
1 acquired pneumonia secondary to his near drowning in the
Philippines. Patient 4 had had a fever during his stay in
mainland China. Patient 6 had fever and left upper
abdominal pain on his arrival in Taiwan after a 4-day trip in
Rangoon, Burma. Patient 8 had septicemic melioidosis 5
years after travel to Thailand. The 13 other episodes (76%)
were considered indigenous. Of the 11 patients with
indigenous melioidosis,  occupation was known for 7 patients
(patients 9 to 15); none were rice farmers. Of the 15 infected
patients, 9 (60%) had underlying diseases (6 had diabetes
mellitus, and 3 had chronic obstructive pulmonary disease),
12 patients (80%) had pneumonia (including 10 with
bacteremia and 1 with concomitant peritonitis), 2 (13%) had
soft-tissue abscess, and 1 (7%) had mycotic aneurysm. Two
patients each had two episodes of infection, separated by 8
and 10 months, respectively. Four patients (27%) died of
melioidosis. One patient (no. 15), who had pneumonia caused
by an organism initially identified as P. aeruginosa and
treated at another hospital with ceftazidime and amikacin for
1 month, died on the third day in our hospital of refractory
pneumonia complicated by empyema and acute respiratory
distress syndrome. Two sets of blood cultures collected upon
admission grew B. pseudomallei. Susceptibility results by the
routine disk susceptibility test showed the organism was
resistant to ceftazidime and amikacin. MICs of the organism
to ceftazidime and amikacin were 32 µg/mL and >256 µg/mL,
respectively (Table 2).
Bacterial Isolates and Biotypes
All B. pseudomallei isolates had characteristic colonial
morphology on trypticase soy agar supplemented with 5%
sheep blood (BBL Becton Dickinson, Microbiology, Cock-
eysville, MD), positive oxidase reaction, and resistance to
colistin and gentamicin. Of the 17 isolates (from eight
patients), two biochemical profiles based on the results of
identification by the API 20NE system were 1156576 (biotype
I; citrate negative) and 1156577 (biotype II; citrate positive).
All isolates tested were Ara-. The probability of identification
of each B. pseudomallei biochemical profiles was 99.9%.
All 17 isolates (from eight patients) studied had similar
FAME profiles, and all had five major FAMEs (each
presenting >3% of the total): 14:0 (tetradecanoic acid), 3-OH-
14:0 (3-hydroxytetradecanoic acid), 16:0 (hexadecanoic acid),
17:0cyc (-cis-9, 10-methylenehexadecanoic acid), 2-OH-16:0
(2-hydroxyhexadecanoic acid), 3-OH-16:0 (3-hydroxyhexade-
canoic acid), 18:1w7c (cis-11-octadecenoic acid), and 19:0cyc
(-cis-11, 12-methyleneoctadecanoic acid). FAME profiles of
these isolates were consistent with the identification of
B. pseudomallei.
Antimicrobial Susceptibilities and Antibiotypes
MICs of 14 antimicrobial agents for the 17 isolates of
B. pseudomallei were determined (Table 2). When MIC
breakpoints for susceptibility and resistance used for non-
Enterobacteriaceae were applied to B. pseudomallei (21),
all isolates were susceptible to amoxicillin-clavulanate,
Figure 1. Cases of melioidosis in Taiwan, by year of diagnosis.
Number above each bar indicates number of episodes with
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piperacillin-tazobactam, imipenem, and meropenem. Most
isolates were intermediate or resistant to ampicillin,
flomoxef, cefepime, aztreonam, amikacin, and ciprofloxacin.
Ceftazidime had in vitro activity equal to or greater than that
of cefotaxime against B. pseudomallei. Two isolates (both from
patient 12) showed high resistance to ceftazidime and cefepime
and intermediate resistance to cefotaxime. Five antibiotypes
(antibiotypes I to V) were identified in the 17 isolates.
RAPD Patterns and Identification
Eight RAPD patterns were identified by use of the three
primers (Figure 2). RAPD patterns of multiple isolates from
the same patients were identical. The two isolates (recovered
10 months apart) from patient 10 belonged to strain 5; two of
the three isolates (recovered 8 months apart) from patient 11
were also identical (strain 6; Table 3). Isolates recovered from
different patients had distinct RAPD patterns.
Table 1. Clinical characteristics of 15 patients in Taiwan with invasive infections caused by Burkholderia pseudomallei
   Underlying
     diseases/    Isolate
Patient Age/     Travel     associated        Clinical     source
no./ref  sex     history     conditions       diagnosis     (date)            Treatment Outcome
1 (13) 46/M Philippines Near drowning Cavitary Blood (9/82) Cephalothin, amikacin (30 d) Surv
  pneumonia
2 (14) 75/F None Liver cirrhosis, Pneumonia, Blood, ascites Cefazolin, gentamicin (1 d) Died
  uremia, DM   peritonitis (8/94)
3 (14) 70/M None None Pneumonia Blood (8/94) Ceftazidime (30 d), amoxicillin- Surv
  clavulanate (3 mo)
4 (15) 70/M China None Mycotic Blood (11/94); Ceftazidime (35 d); amoxicillin- Surv
  aneurysm   aortic tissue   clavulanate (6 mo)
  (12/94)
5 (16) 75/M None DM Pneumonia Blood (11/96) Ceftazidime (14 d); amoxicillin- Surv
  clavulanate (2 mo)
6 (17) 51/M Burma DM Pneumonia, adrenal Blood (7/97) Ceftazidime (2 d); cotrimoxazole Surv
  gland abscess   (60 d)
7 (18) 40/M None DM Pneumonia, ARDS Blood (7/97) Moxalactam (9 d); netilmicin (9 d); Died
  erythromycin (9 d)
8 (PR) 56/M Thailand None Pneumonia Blood-A (11/96) Ceftazidime, gentamicin (1 d) Died
9 (PR) 67/M None COPD Pneumonia Blood-B (1/97) Ceftazidime (14 d); amoxicillin- Surv
  clavulanate (2 d)
10 (PR) 73/M None Prostate cancer Cavitary Lung aspirate- Ciprofloxacin (5 mo) Surv
  with bone   pneumonia   C1 7/97);
  metastasis;   RAPDa
  DM; cypro-   patterns
  terone and   sputum-
  leuprolide   C2 (7/97)
  acetate use
11 (PR) 76/F None None Septic arthritis, Blood-D1; Ciprofloxacin (4 mo); Surv
  subcutaneous   blood-D2;   surgical drainage
  abscess   synovial
  fluid-D3;
  abscess fluid-
  D4; wound
  drainage-D5;
  all 9/98
12 (PR) 58/M None None Subcutaneous Abscess fluid-E1 Piperacillin (10 d); Surv
  abscess   (4/99); abscess   ciprofloxacin (14 d)
  fluid-E2
  (2/2000)
13 (PR) 66/M None DM Pneumonia, Lung aspirate- Imipenem (10 d); Surv
  arthritis, sub-   F1 (5/99);   ciprofloxacin (2 mo);
  cutaneous   synovial fluid-   meropenem (1 mo);
  abscess   F2 (5/99);   amoxicillin-
  abscess   clavulanate (4 mo)
  aspirate-F3
  (1/2000)
14 (PR) 74/M None COPD Pneumonia Blood-G (9/99) Ceftazidime, amikacin Surv
  (14 mo); ciprofloxacin
  (2 mo)
15 (PR) 70/M None COPD, TB Pneumonia, Blood-H1 Ceftazidime, amikacin (1 mo) Died
  empyema;   Blood-H2
  ARDS   (1/2000)
Abbreviations used in this table: ARDS, adult respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; d, day; DM, diabetes mellitus; TB,
tuberculosis; mo, month; PR, present report; surv, survived.Vol. 7, No. 3, May–June 2001 Emerging Infectious Diseases 431
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Conclusion
Between January 1982 and 1994, one episode of
melioidosis was identified in Taiwan. From 1994 to May 2000,
16 more cases occurred. Whether these figures represent an
actual increase in B. pseudomallei infections in Taiwan or
better recognition of this organism by microbiology
laboratories is difficult to clarify. In NTUH, the first
clinical isolate of B. pseudomallei was recognized in 1980
(the medical record and isolate are now unavailable). Since
then, improved laboratory procedures and increasing
alertness of laboratory staffs permit more accurate
identification of this organism. However, no B. pseudomallei
isolate was identified in our laboratory from 1981 to 1995.
Thus, from our vantage point, the observed increase in
cases of melioidosis is indeed an emerging problem of the
last 5 years.
Most of these infections were indigenous. All strains,
whether imported or indigenous, were genetically distinct.
Different patients were infected with different strains,
indicating that spread of strains (intercontinental or within
this island), as with Penicillium marneffei (another emerging
pathogen in Taiwan), did not occur (23). Our data suggest that
Taiwan should be considered a melioidosis-endemic area, in
addition to China, Australia, and Southeast Asia.
Melioidosis has been called the great mimicker because of
its protean clinical features (1,7). The most common clinical
sign is an acute pulmonary infection (as in our study), though
its chronic pulmonary form often resembles tuberculosis
(3,16). When localized, melioidosis may cause abscess
formation in skin, soft tissue, joints, and visceral organs (1).
Melioidosis can become a latent infection that later (as much
as 26 years after initial exposure) reactivates into a full-blown
illness (even with acute septicemia) (1,12). The content of
Ara- B. pseudomallei in the soil of a geographic area has been
documented to correlate directly with the incidence of
melioidosis in that area (5,6). In our study, all but four
patients had no prior exposure to well-known disease-
endemic areas. Therefore, the strains of B. pseudomallei they
acquired might have originated in Taiwanese soil. Unlike
other reports (24), most (87%) of our patients were male. Also,
all but one patient with indigenous infection were >65 years,
and none were rice farmers or obviously had heavy exposure
to soil. Environmental surveys for the presence of this
organism in the soil of Taiwan, especially in rice fields, are
ongoing; thus far, B. pseudomallei has been isolated from two
soil samples (data not shown). Although Ara+ B. pseudomallei
has been reported to cause severe infection (10), all isolates
Table 2. Susceptibilities and antibiotypes of 17 isolates of Burkholderia pseudomallei isolated in Taiwan from November 1996 to January 2000
Patient no./                                                                               MIC (mg/mL)a Antibiotic
isolate AM AMC PZP CTX CAZ FEP FLO ATM IPM MEM   AN CIP TRO MOX      type
8/A 64 8 0.5   4   4 16 128 16 0.5 1     64 2 2 2   I
9 / B 6 4 81   4  41 61 2 8 1 6 0 . 5 1   1 2 8 2 2 2   I
10/C1, 2 64 8 0.5   4   4 16 128 16 0.5 1     32 1 2 2  II
11/D1, 2, 3, 4, 5 64 8 0.5   2   1 16 128 16 0.5 1     32 2 4 1 III
12/E1, 2 64 8 0.5   2   1   8 128 16 0.5 1     32 2 4 1 III
13/F1, 2, 3 64 8 0.5   2   1 16 128 16 0.5 1     16 2 4 1 III
14/G 16 2 0.12   2   1   8   64   8 0.25 0.5     64 1 1 1 IV
15/H1, 2 64 8 1 16 32 64 128 32 0.5 2 >256 4 8 4  V
aAM, amoxicillin; AMC, amoxicillin-clavulanate; PZP, piperacillin-tazobactam; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; FLO, flomoxef; ATM,
aztreonam; IPM, imipenem; MEM, meropenem; AN, amikacin; CIP, ciprofloxacin; TRO, trovafloxacin; MOX, moxifloxacin.
Figure 2. Random amplified polymorphic DNA (RAPD) patterns of 16
isolates of Burkholderia pseudomallei generated by arbitrarily
primed polymerase chain reaction with the primers M13 (upper
panel) and ERIC1 (lower panel). Lanes: M, molecular size marker; 1,
isolate A; 2, isolate B; 3 and 4, isolates C1 and C2; respectively; 5 to
9, isolates D1 to D5; 10 and 11, isolates E1 and E2, respectively; 12,
isolates G; 13 and 14, isolates F1 and F2, respectively; and 15 and 16,
isolates H1 and H2, respectively. (See Table 3 for designation of
isolates).
Table 3. Phenotypic and genotypic characteristics of 17 isolates of
Burkholderia pseudomallei
                     RAPDa patterns
Isolate(s)/   Anti- M13/ERIC1/
patient no. biotype Biotype    OPH-3 Strain
A/8   I A a 1
B/9   I A b 2
C1, C2/10  II A c 3
D1, D2, D3, D4, D5/11 III A d 4
E1, E2/12 III A e 5
F1, F2, F3/13 III A f 6
G/14 IV B g 7
H1, H2/15  V A h 8
aRAPD = Random amplified polymorphic DNA.432 Emerging Infectious Diseases Vol. 7, No. 3, May–June 2001
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causing melioidosis in our study were Ara-. Our findings
support previous observations (1,5,6).
B. pseudomallei are frequently intrinsically resistant to
many antibiotics, including aminoglycosides and first- or
second-generation cephalosporins (25,26). Current recom-
mendations for therapy of severe melioidosis include
intravenous ceftazidime or imipenem for 10 days to 4 weeks
(25,26), followed by maintenance therapy with oral
amoxicillin-clavulanate or a combination of trimethoprim-
sulfamethoxazole and doxycycline for 10 to 18 weeks (27-31).
Cefotaxime and ceftriaxone are both less active than
ceftazidime against B. pseudomallei in vivo and in vitro (28).
However, the observation of ceftazidime resistance’s
emerging during treatment has been previously reported (30).
Its occurrence in our patient 15 might be related to the
presence of an empyema. In areas in which melioidosis is
endemic, empirical regimens that contain cefotaxime or
ceftriaxone for the treatment of severe community-acquired
pneumonia or septicemia may not be appropriate.
Some investigators suggest that melioidosis is a
facultative intracellular infection (25). The failure of beta-
lactam antibiotics to penetrate intracellular sites and kill
nonmultiplying dormant bacteria may explain the frequent
relapses of melioidosis after treatment with these drugs (25).
On the other hand, relapse is documented to be less common
(10% versus 30%) in patients who complete a full course of
antibiotic treatment (32). Our two patients who had recurrent
infections both received oral ciprofloxacin for 2 or 8 weeks.
Nearly all isolates had MICs ranging from 1 µg/mL to 4 µg/mL
for the three newer fluoroquinolones tested. Further studies
are needed to determine the clinical efficacy of these newer
fluoroquinolones for treating melioidosis and their role in
preventing future relapse.
Several molecular typing methods have been applied to
B. pseudomallei to evaluate the strain relationship in isolates
recovered from humans and environment (33-37). Among
these methods, RAPD typing has also been documented to be
useful for analyzing isolates that cause recurrent infection or
reinfection (35). In our study, RAPD typing using three
primers clearly demonstrated the genetic diversity of isolates
from different patients (with either imported or indigenous
infections). In addition, this method showed that multiple
isolates from the same patient and isolates causing recurrent
infections were genetically identical. The microbial identifi-
cation system, based on cellular FAME analysis by use of gas
chromatography, is an established method for identifying
species of bacteria and fungi and showing clustering in
bacterial and fungal strains (22,23). Although all our isolates
of  B. pseudomallei had identical FAME profiles, cluster
analysis of these esters (data not shown) failed to provide
acceptable discriminatory power for typing the isolates.
In conclusion, Taiwan should be included as an endemic
area of melioidosis, and physicians managing patients in
Taiwan should be alert to the possibility that this organism
might cause community-acquired pneumonia and sepsis.
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